

## Special Issue

# Novel Biomarkers: Validity, Evaluation and Biological Roles for Breast Cancer

### Message from the Guest Editors

Dear colleagues, The routine work of the surgical pathologist is rapidly changing due to breakthroughs in, e.g., molecular pathology. The diagnostic process is increasingly precise, and potential prognostic and predictive biomarkers are constantly being developed and presented to the multidisciplinary cancer team. In order to attain clinical utility, it is, however, of utmost importance to secure not only clinical validity with significant results from clinical studies supporting benefit in specific patient groups in terms of overall or disease-free survival, but also analytical validity securing reproducible and robust analytical methods encompassing, e.g., conventional histopathology, immunohistochemical stainings, and molecular pathology. This Special Issue of *Cancers* will focus on novel diagnostic, prognostic, and predictive markers in breast cancer, including the use of digital solutions to evaluate biomarker expression. The issue will further focus on the necessity to secure the analytical validity for a biomarker to be applicable in the clinical setting. The issue will encompass new research articles and timely reviews.

### Guest Editors

Prof. Trine Tramm

Department of Pathology, Aarhus University Hospital, Palle Juul-Jensens Boulevard, Aarhus N, Denmark

Prof. Anne Vibeke Lærnholm

1. Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark

2. Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark

### Deadline for manuscript submissions

closed (30 April 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/65792](https://mdpi.com/si/65792)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)